872 related articles for article (PubMed ID: 26194120)
1. Pharmacological basis and scientific rationale underlying the targeted use of inhaled corticosteroid/long-acting β2-adrenergic agonist combinations in chronic obstructive pulmonary disease treatment.
Pelaia G; Muzzio CC; Vatrella A; Maselli R; Magnoni MS; Rizzi A
Expert Opin Pharmacother; 2015; 16(13):2009-21. PubMed ID: 26194120
[TBL] [Abstract][Full Text] [Related]
2. The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD.
Hanania NA
Pulm Pharmacol Ther; 2008; 21(3):540-50. PubMed ID: 18280761
[TBL] [Abstract][Full Text] [Related]
3. Comparing a fixed combination of budesonide/formoterol with other inhaled corticosteroid plus long-acting beta-agonist combinations in patients with chronic obstructive pulmonary disease: a review.
Solidoro P; Patrucco F; Bagnasco D
Expert Rev Respir Med; 2019 Nov; 13(11):1087-1094. PubMed ID: 31498714
[No Abstract] [Full Text] [Related]
4. Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS.
Latorre M; Novelli F; Vagaggini B; Braido F; Papi A; Sanduzzi A; Santus P; Scichilone N; Paggiaro P
Pulm Pharmacol Ther; 2015 Feb; 30():44-50. PubMed ID: 25445928
[TBL] [Abstract][Full Text] [Related]
5. Chronic obstructive pulmonary disease: Useful medications for patients with recurrent symptoms.
Prescrire Int; 2016 Nov; 25(176):272-277. PubMed ID: 30715829
[TBL] [Abstract][Full Text] [Related]
6. A re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary disease.
D'Urzo A; Donohue JF; Kardos P; Miravitlles M; Price D
Expert Opin Pharmacother; 2015; 16(12):1845-60. PubMed ID: 26194213
[TBL] [Abstract][Full Text] [Related]
7. Role of Long-Acting Muscarinic Antagonist/Long-Acting β
Petite SE
Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560
[TBL] [Abstract][Full Text] [Related]
8. [Inhaled corticosteroid/beta-2 agonist therapy in moderate COPD].
Yıldırım N
Tuberk Toraks; 2010; 58(2):192-201. PubMed ID: 20865575
[TBL] [Abstract][Full Text] [Related]
9. The use of long acting β₂-agonists, alone or in combination with inhaled corticosteroids, in chronic obstructive pulmonary disease (COPD): a risk-benefit analysis.
Cave AC; Hurst MM
Pharmacol Ther; 2011 May; 130(2):114-43. PubMed ID: 21276815
[TBL] [Abstract][Full Text] [Related]
10. LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes.
Hizawa N
Int J Chron Obstruct Pulmon Dis; 2015; 10():1093-102. PubMed ID: 26089659
[TBL] [Abstract][Full Text] [Related]
11. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study.
Larsson K; Janson C; Lisspers K; Jørgensen L; Stratelis G; Telg G; Ställberg B; Johansson G
J Intern Med; 2013 Jun; 273(6):584-94. PubMed ID: 23495860
[TBL] [Abstract][Full Text] [Related]
12. Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease--The Shifting Treatment Paradigm.
Wilkie M; Finch S; Schembri S
COPD; 2015; 12(5):582-90. PubMed ID: 25774769
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting.
Perrone V; Sangiorgi D; Buda S; Degli Esposti L
Int J Chron Obstruct Pulmon Dis; 2016; 11():2749-2755. PubMed ID: 27853362
[TBL] [Abstract][Full Text] [Related]
14. Inhaled corticosteroids as combination therapy with beta-adrenergic agonists in airways disease: present and future.
Chung KF; Caramori G; Adcock IM
Eur J Clin Pharmacol; 2009 Sep; 65(9):853-71. PubMed ID: 19557399
[TBL] [Abstract][Full Text] [Related]
15. Long-acting beta-agonists and their association with inhaled corticosteroids in COPD.
Fuso L; Mores N; Valente S; Malerba M; Montuschi P
Curr Med Chem; 2013; 20(12):1477-95. PubMed ID: 23409722
[TBL] [Abstract][Full Text] [Related]
16. Advances in asthma and COPD treatment: combination therapy with inhaled corticosteroids and long-acting beta 2-agonists.
Miller-Larsson A; Selroos O
Curr Pharm Des; 2006; 12(25):3261-79. PubMed ID: 17020533
[TBL] [Abstract][Full Text] [Related]
17. A review of the efficacy and safety of fluticasone propionate/formoterol fixed-dose combination.
Kilaru SC; Bansal AG; Naik VS; Lopez M; Gogtay JA
Expert Rev Respir Med; 2022 May; 16(5):529-540. PubMed ID: 35727177
[TBL] [Abstract][Full Text] [Related]
18. Emerging therapeutic strategies in COPD.
Babu KS; Morjaria JB
Drug Discov Today; 2015 Mar; 20(3):371-9. PubMed ID: 25462534
[TBL] [Abstract][Full Text] [Related]
19. Three-month treatment response and exacerbation in chronic obstructive pulmonary disease.
Lee JS; Rhee CK; Yoo KH; Lee JH; Yoon HI; Kim TH; Kim WJ; Lee J; Lim SY; Park TS; Lee JS; Lee SW; Lee SD; Oh YM
J Korean Med Sci; 2015 Jan; 30(1):54-9. PubMed ID: 25552883
[TBL] [Abstract][Full Text] [Related]
20. Advances in drug delivery: Is triple therapy the future for the treatment of chronic obstructive pulmonary disease?
Salama RO; Young PM; Rogueda P; Lallement A; Iliev I; Traini D
Expert Opin Pharmacother; 2011 Aug; 12(12):1913-32. PubMed ID: 21714776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
